Sacituzumab Biosimilar, Trop-2 Monoclonal Antibody

Additional Information:
| Sacituzumab Biosimilar, Human Trop-2 Monoclonal Antibody Recombinant Humanized IgG1 Monoclonal Antibody. Isotype: Human IgG1 kap|The monoclonal antibody sacituzumab biosimilar was produced in mammal cells. Specificity/Sensitivity: The monoclonal antibody sacituzumab biosimilar specifically binds to the human Trop-2 protein. Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological |0.2 uM filtered solution, pH 6.2, no stabilizers or preservatives. Endotoxin: Purity: >95% by SDS-|The monoclonal antibody sacituzumab is shipped with ice |Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |Background What is sacituzumab biosimilar research grade? Sacituzumab Biosimilar uses the same protein sequences as the therapeutic antibody sacituzumab. Sacituzumab govitecan is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothel cancer. Triple-negative breast cancer is a type of breast cancer that tests negative for estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 (HER2) protein. Therefore, triple-negative breast cancer does not respond to hormonal therapy medicines or medicines that target HER2. Sacituzumab govitecan is a conjugate of the humanized anti-Trop-2 monoclonal antibody linked with SN-38, the active metabolite of irinotecan. Each antibody having on average 7.6 molecules of SN-38 attached. SN-38 is too toxic to administer directly to |Tusamitamab biosimilar, research grade, anti-human CEACAM5 monoclonal antibody Rovalpituzumab biosimilar, research grade, anti-human DLL3 monoclonal antibody Trastuzumab biosimilar, research grade, anti-human HER2 monoclonal antibody Cofetuzumab biosimilar, research grade, anti-human PTK7 monoclonal antibody Ifinatamab biosimilar, research grade, anti-human B7-H3 (CD276) monoclonal antibody Sacituzumab biosimilar, research grade, anti-human Trop-2 monoclonal antibody Gemtuzumab biosimilar, research grade, anti-human CD33 monoclonal antibody Polatuzumab biosimilar, research grade, anti-human CD79B monoclonal antibody Cetuximab biosimilar, research grade, anti-human EGFR monoclonal antibody